Infectious DiseaseNCT05400824
Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
An observational study of Infectious Disease and Cardiovascular Diseases, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
Trial summary
The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France). Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics. Read more about this study
- Who is it for?
- Ages 18 to 67 years
- Conditions the study is for
- Infectious Disease, Cardiovascular Diseases, General Population
- What is being tested?
- Blood, DNA, feces, urine, hair and skin microbiota collection
- How many people
- 2,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 May 2022to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 67 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult men and women ramdomly selected from the voter registration lists in La Réunion island
Who may be able to join
- 18-67 years
- given consent for genetic analysis,
- written consent for participating in the study
Who cannot join
- judicial protection or guardianship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Hospitalier Universitaire de La Réunion
La Réunion, Saint-Pierre, 97448
About this study
Official title: Pathologies métaboliques et Infectieuses en Population générale à La Réunion : étude REUNION
The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France).
Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics.
Read the detailed description
Overall, 2000 men and women will be recruited during two years for an extensive clinical examination including a microbiota, blood, hair and DNA collection, cognitive tests, autonomous nervous system assessment, spirometry, pulse wave velocity measurement, a carotid doppler echo tracking.
- Being tested
- Blood, DNA, feces, urine, hair and skin microbiota collection
- Keywords
- epidemiology, risk factors, prevalence, cognitive impairment, dengue, hypertension, dyslipidemia, social inequalities, autonomous nervous system
- Medical subject headings
- Communicable Diseases, Cardiovascular Diseases, Metabolic Diseases, Cognitive Dysfunction, Dengue, Hypertension, Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood, DNA, feces, urine, hair and skin microbiota collectionDiagnostic test
Also called Ewing test, Spirometry, EKG, cognitive, anxiety and depression tests
See above
| Study group | Role | What they receive |
|---|---|---|
| general population | Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion Receives: Diagnostic Test: Blood, DNA, feces, urine, hair and skin microbiota collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of cardiometabolic diseases
Prevalence rates for diabetes, hypertension, obesity, dyslipidemia, smoking and subclinical atherosclerosis markers
Measured: cross sectional (at inclusion)
Prevalence of infectious diseases
Seroprevalence rates for chikungunya, dengue, zika, covid19
Measured: cross sectional (at inclusion)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2022
- Study start1 May 2022
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infectious DiseaseStudies of the same condition, open and under way.
- More trials run by Institut National de la Santé Et de la Recherche Médicale, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Maxime COURNOT, MD, PhD, Principal investigator, Institut National de la Santé Et de la Recherche Médicale, FranceOlivier MEILHAC, PhD, Study director, Institut National de la Santé Et de la Recherche Médicale, FrancePatrick MAVINGUI, PhD, Study director, Institut National de la Santé Et de la Recherche Médicale, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05400824
- Sponsor's protocol ID
- C19-68
- Other IDs
- 2020A0209435
- Status last verified
- Jul 2026
- First submitted
- 27 May 2022
- Last updated
- 10 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pathologies métaboliques et Infectieuses en Population générale à La Réunion : étude REUNION
- ClinicalTrials.gov ID
- NCT05400824
- Acronym / sponsor ID
- C19-68
- Keywords
- epidemiology, risk factors, prevalence, cognitive impairment, dengue, hypertension, dyslipidemia, social inequalities
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceOther government
- Study start
- 1 May 2022 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 2 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France).
Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics.
Detailed description
Overall, 2000 men and women will be recruited during two years for an extensive clinical examination including a microbiota, blood, hair and DNA collection, cognitive tests, autonomous nervous system assessment, spirometry, pulse wave velocity measurement, a carotid doppler echo tracking.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| general population | – | Diagnostic Test: Blood, DNA, feces, urine, hair and skin microbiota collectionObservational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion |
Who may qualify
- Ages
- 18 to 67 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult men and women ramdomly selected from the voter registration lists in La Réunion island
Key inclusion criteria (3 listed)
- 18-67 years
- given consent for genetic analysis,
- written consent for participating in the study
Key exclusion criteria (1 listed)
- judicial protection or guardianship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood, DNA, feces, urine, hair and skin microbiota collectionAlso: Ewing test, Spirometry, EKG, cognitive, anxiety and depression testsSee above | Diagnostic test | general population |
Primary outcome
Prevalence of cardiometabolic diseases
Time frame: cross sectional (at inclusion)
Prevalence rates for diabetes, hypertension, obesity, dyslipidemia, smoking and subclinical atherosclerosis markers
Prevalence of infectious diseases
Time frame: cross sectional (at inclusion)
Seroprevalence rates for chikungunya, dengue, zika, covid19
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- official website of the French National Institute for Health and Medical ResearchLink provided by the sponsor.
Related trials for Infectious Disease
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Active, not recruitingPhase 2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Chronic Hepatitis B Virus Infection, Hepatitis B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maxime COURNOT, MD, PhD principal investigator
Institut National de la Santé Et de la Recherche Médicale, France
Olivier MEILHAC, PhD study director
Institut National de la Santé Et de la Recherche Médicale, France
Patrick MAVINGUI, PhD study director
Institut National de la Santé Et de la Recherche Médicale, France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infectious Disease and Cardiovascular Diseases, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maxime COURNOT (+262262938811, maxime.cournot@inserm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of cardiometabolic diseases (time frame: cross sectional (at inclusion)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.